07-Jun-2002 Urge incontinence pelvic floor exercises- cystoscopy showed irritative bladder 27-Feb-2002 Essential hypertension 16-Dec-2001 Gout Medications Acute Drug Dosage Quantity Ibuprofen One To Be 56 tablet Three Times Daily PRN Repeat Drug Dosage Quantity Bisoprolol 1.25mg tablets One To Be Daily 56 tablet ASD Warfarin 5mg 100 tablet ASD 100 tablet Warfarin 3mg Aspirin 75mg tablets One To Be Daily 56 tablet Bumetanide 1mg tablets One To Be Taken on Alternative 28 tablet Days Omeprazole 20mg gastro-resistant One To Be Taken Each Morning 56 capsule capsules Citalopram 10mg tablets One To Be Taken Daily 56 tablet Zerobase 11% cream Use PRN 500 gram Atorvastatin 10mg tablets One To Be Taken Daily 56 tablet Laxido Orange oral powder sachets 1 sachet mixed with water SD 90 sachet Donepezil 10mg tablets 1 to be Taken Daily 56 tablets Hydroxyzine 10mgs tablets 1 to be Taken at night 56 tablets Ramipril 5mgs tablets 1 to be Taken Daily 56 tablets Co-codamol 8/500 tablets 1-2 tablets QDS PRN 112 tablets
07-Jun-2002 Urge incontinence pelvic floor exercises- cystoscopy showed irritative bladder 27-Feb-2002 16-Dec-2001 Essential hypertension Gout Medications Acute Drug Dosage Quantity Ibuprofen One To Be 56 tablet Three Times Daily PRN Repeat Drug Dosage Quantity Bisoprolol 1.25mg tablets Warfarin 5mg Warfarin 3mg One To Be Daily ASD ASD 56 tablet 100 tablet 100 tablet Aspirin 75mg tablets One To Be Daily 56 tablet Bumetanide 1mg tablets One To Be Taken on Alternative Days 28 tablet Omeprazole 20mg gastro-resistant capsules One To Be Taken Each Morning 56 capsule Citalopram 10mg tablets One To Be Taken Daily 56 tablet Zerobase 11% cream Use PRN 500 gram Atorvastatin 10mg tablets One To Be Taken Daily 56 tablet Laxido Orange oral powder sachets 1 sachet mixed with water SD 90 sachet Donepezil 10mg tablets 1 to be Taken Daily 56 tablets Hydroxyzine 10mgs tablets 1 to be Taken at night 56 tablets Ramipril 5mgs tablets 1 to be Taken Daily 56 tablets Co-codamol 8/500 tablets 1-2 tablets QDS PRN 112 tablets
Case%20Scenario%20Polypharmacy%20CLG%20-%20Meeting%202.docx